Novo Nordisk backer buys Catalent for $16.5 billion

It would appear pharmaceuticals and biotechnology is still a fertile industry for dealmaking.

Novo Holdings, the largest shareholder in Danish drugs giant Novo Nordisk, just announced the $16.5 billion takeover of US-listed Catalent, provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products...


Register for free to see rest of this article and all public articles from Betaville

Login / Register
Date: Monday, 5 February 2024, 11:24 am

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation